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Abstract
Background: The Step trial raised the possibility that uncircumcised men with pre-existing Ad5 neutralizing antibodies
carried an increased risk of HIV infection after vaccination. Thus, understanding Ad seropositivity in humans is important to
the development of an AIDS vaccine. Here, we analyze the impact of different Ad5-specific neutralizing antibodies on
immune function and clinical outcome.
Methods and Findings: Ad seropositivity in the Step trial volunteers was analyzed using chimeric rAd5/35 vectors to
characterize their specificity for Ad5 fiber and non-fiber external (capsid) proteins. Immune responses and HIV seropositivity
were correlated with the specificity of Ad5-neutralizing antibodies. Neutralizing antibodies induced by the vaccine in Ad5
seronegative subjects were directed preferentially to Ad5 capsid proteins, although some fiber-neutralizing antibodies
could be detected. Pre-vaccination Ad5 serostatus did not affect the capsid-directed response after three vaccinations. In
contrast, anti-fiber antibody titers were significantly higher in volunteers who were Ad5 seropositive prior to vaccination.
Those Ad5 seropositive subjects who generated anti-capsid responses showed a marked reduction in vaccine-induced CD8
responses. Unexpectedly, anti-vector immunity differed qualitatively in Ad5 seropositive participants who became HIV-1
infected compared to uninfected case controls; Ad5 seropositive participants who later acquired HIV had lower neutralizing
antibodies to capsid. Moreover, Ad35 seropositivity was decreased in HIV-infected subjects compared with uninfected case
controls, while seroprevalence for other serotypes including Ad14, Ad28 and Ad41 was similar in both groups.
Conclusions: Together, these findings suggest that the case subjects were less immunologically responsive prior to
infection. Subjects infected during the Step trial had qualitative differences in immunity that increased their risk of HIV-1
infection independent of vaccination.
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Introduction
The Step study was a phase IIB clinical trial designed to test a
recombinant adenovirus 5 (rAd5) based HIV vaccine in 3000
participants who were seronegative or seropositive for pre-existing
Ad5 neutralizing antibodies. An interim analysis of Step study
participants revealed no beneficial effect of vaccination on HIV
viral load or acquisition of infection in vaccinated individuals vs.
placebo controls and also showed a trend towards increased HIV
infection after vaccination in uncircumcised men with pre-existing
Ad5 neutralizing antibodies [1,2]. Thus, understanding the nature
and immune effects of Ad5 seropositivity in humans is important
for the development of rAd-based vaccines against AIDS.
Ad5 viruses are non-enveloped virions composed of fiber and
two major capsid proteins, hexon and penton base (penton), all of
which are exposed on the virion surface. Neutralizing antibodies to
these proteins mediate viral inactivation. Specifically, anti-fiber
antibodies can prevent viral entry, and antibodies to other capsid
proteins can also interfere with viral uptake and viral endosomal
escape during cell infection [3]. These antibodies also synergize
with each other to achieve maximum viral neutralization [3,4].
Prior research on pre-existing neutralizing antibodies to Ad5 in
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antibodies to the whole Ad5 virion [1,2]. We have previously
developed chimeric rAd vectors that can be used to analyze the
role of specific neutralizing antibodies against individual viral
proteins [5]. The panel of rAd reporters included two chimeric
vectors and the parental, unmodified rAd5 and rAd35 vectors.
The rAd35 vector was used as the control backbone because
human sera rarely neutralize this serotype at high titers and
participants seropositive for this control backbone confound the
analysis and must be excluded from the subsequent immune
analysis. The two chimeric vectors are rAd5 Fiber (F)35 and
rAd35 F5 vectors, with the fiber of Ad35 grafted onto rAd5 or with
the fiber of Ad5 grafted onto rAd35, respectively. rAd5 F35
vectors were used to detect neutralizing antibodies to Ad5 capsid
and rAd35 F5 vectors were used to detect anti-Ad5 fiber
neutralizing antibodies. The properties of these reporter vectors
reflect those found on the native Ad serotypes and therefore can be
used to detect the specificity and function of the respective viral
components and analyze anti-Ad immunity in humans [5].
Analysis of sera from participants in the HVTN 204 trial has
shown that the distribution of individual capsid-specific neutral-
izing antibodies varies among these sera, and the pre-existing
fiber-specific neutralizing antibodies correlated with both a
reduced response rate and the magnitude of anti-Gag T-cell
responses induced by DNA prime and rAd5 boost HIV vaccines
[5].
The major objectives of this study were to determine the
specificity of neutralizing antibodies (Nab) to Ad5 fiber and major
capsid proteins (hexon and penton base) and the potential
association with immunogenicity and risk of infection in
participants of the Step trial. This analysis provided an
opportunity to determine whether natural infection by adenovirus
stimulated neutralizing antibodies to different Ad5 viral proteins
than rAd5 vector vaccination alone and whether they might exert
differential effects on vaccine immunogenicity that could affect
susceptibility to HIV infection. Finally, we sought to determine
whether participants who became infected despite HIV vaccina-
tion developed anti-Ad5neutralizing antibodies with distinct
specificities. An understanding of the nature of anti-Ad5 immunity
and its effect on the Step trial has implications for the design of
next generation vectors for AIDS vaccines.
Results
MRK Ad5 vaccination induced neutralizing antibodies to
the Ad5 fiber protein and capsid proteins in Ad5
seronegative subjects
To determine whether vaccine recipients developed antibodies
to Ad5 after vaccination, we analyzed sera from 22 participants
prior to vaccination and at week 4, 8, and 30. At day 0, pre-
existing Nabs to Ad5 were not detected in 11 Ad5 seronegative
participants (Figure 1A, upper panel) and the sera from two
participants were excluded from subsequent analysis because anti-
Ad35 Nab were detected, which prevented categorization of the
anti-Ad5 Nab activities based on the two chimeric reporter vectors
that utilized Ad35 components. At week 4 (after the first
vaccination), all of the remaining 9 participants became Ad5
seropositive, and their Nabs were directed to capsid proteins other
than fiber in 4 participants or to both fiber and capsid in the other
5 participants (Figure 1A; lower panel, capsid, fiber + capsid). The
specificity of this Nab response changed over the course of
vaccination. By the third vaccination at week 30, all 9 participants
developed Nabs to both fiber and capsid proteins (Figure 1A,
lower panel, 9 participants with undetectable anti-Ad35 neutral-
izing antibodies were analyzed). These results indicate that
vaccination readily generated high titers of Nab to the capsid
and weakly induced neutralizing humoral immunity solely to the
fiber. This trend was also confirmed in the median titer generated
by vaccination (Figure 1A, upper panel). While a high titer of Nab
to the capsid was generated after a single vaccination, there was a
low titer of anti-fiber Nab present in these participants, and it
remained at least 10-fold lower than anti-capsid antibodies despite
a gradual increase of Nab to the fiber after vaccination.
Characterization of neutralizing antibodies to Ad5 fiber
and capsid proteins in the presence of pre-existing Ad5
immunity
Pre-existing immunity to Ad5 was documented in 11 Ad5
seropositive participants whose sera contained Nabs to Ad5 prior
to the first immunization. In contrast to the vaccine-induced Nabs
to Ad5 elicited by vaccination in the seronegative group,
neutralizing activity directed to the fiber was detected in all 11
pre-immune vaccine sera (Figure 1B, upper panel). One
participant was excluded from further analysis due to high titers
of anti-Ad35 Nabs detected at week 4. Of the remaining 10
participants, one subject’s Nabs were directed exclusively to the
fiber, while the other 9 participants had Nabs to both fiber and
capsid prior to vaccination. After the first immunization, all sera
showed an increase in the neutralization titer directed to both fiber
and capsid (Figure 1B, lower panel, 10 participants with
undetectable anti-Ad35 neutralizing antibodies were analyzed).
Comparing the Nab titers of seropositives with seronegatives, we
found, as expected, that the titers of anti-Ad5, anti-Ad5 capsid,
and anti-Ad5 fiber Nab were all higher in seropositives compared
to the seronegatives (Figure 1C, day 0). After the first vaccination,
the anti-capsid titers increased more than the anti-fiber response
(Figure 1C, week 8). After a second vaccination, the magnitude of
this difference was reduced; by week 30, there was no significant
difference in terms of Nab titers to Ad5 or to Ad5 capsid. On the
other hand, the titer of Nab to Ad5 fiber in the seronegative group
was significantly lower than in the seropositive groups at all time
points (Figure 1C; Fiber, p,0.05).
Characterization of pre-existing neutralizing antibody to
fiber and capsid proteins in HIV-uninfected participants
We examined 179 sera at day 0 from HIV-uninfected subjects.
Of these, 51 serum samples were classified as Ad5 seronegative
(titers ,18). The remaining 128 samples were Ad seropositive
(titers $18). These results were largely consistent with testing by
the HVTN laboratory, although 9 seronegatives in the HVTN
assay were determined to be seropositive with low titers due to the
sensitivity of our assay to detect low titer samples. When the Ad5
seropositive group was further analyzed to determine the
specificity of their responses, we found a correlation between
anti-Ad5 titers with either the anti-capsid (Figure 2A; Ad5 F35
Spearman correlation r=0.79) or the anti-fiber (Figure 2B; Ad35
F5 Nab titer, Spearman correlation r=0.63), and a correlation
between anti-Ad5 capsid (Ad5 F35) and anti-Ad5 fiber (Ad35 F5,
Figure 2D Spearman correlation r=0.43) based on a nonpara-
metric correlation (Spearman) analysis (Figure 2, A, B, and D,
p,0.0001),while there was no correlation between anti-Ad5 and
anti-Ad35 Nab titers (Spearman correlation r=20.04, p.0.05,
Figure 2C), documenting the serotype specificity of the Ad5
seropositive group. After excluding 12 samples due to anti-Ad35
titers, we were able to characterize the neutralization targets in
116 samples. Nab to both Ad5 fiber and Ad5 capsid were detected
in a majority of the samples (89%), while Nab to capsid only or
Immune Basis of HIV-1 Infection in Step Trial
PLoS ONE | www.plosone.org 2 April 2012 | Volume 7 | Issue 4 | e33969Figure 1. MRKAd5 HIV vaccine generated neutralizing antibodies to Ad5 capsid proteins more efficiently than to Ad5 fiber. The
titers of Nab to Ad5, Ad5 F35, Ad35 and Ad35 F5 were determined in Ad5 seronegatives and Ad5 seropositives following vaccinations. The minimum
detectable titer is at 1:12 serum dilution and the maximum titer is at the end point dilution to achieve 90% neutralization of the vector. The
development of Nab in baseline seronegatives (A) or seropositives (B) at 4 weeks after each vaccination was also shown. A (lower panel) and B (lower
panel) show the Nab targets in these sera, excluding sera samples with high anti-Ad35 Nab titers which confound the categorization of the Nab
target. (C) Direct comparison of the titer of Nabs to Ad5, or Ad5 capsid, or Ad5 fiber between baseline seronegatives and seropositives. Day 0: pre-
vaccination; Week 4: 4 weeks after the first vaccination; Week 8: 4 weeks after the second vaccination; Week 30: 4 weeks after the third vaccination.
doi:10.1371/journal.pone.0033969.g001
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samples (Figure 3A, 7% and 4%, respectively).
Figure 2. The titers of Nab to Ad5, Ad5 F35, Ad35, and Ad35 F5 were determined in pre-vaccination sera from 128 HIV-uninfected
participants, and the correlation between the titers of Nab to each vector were analyzed with p,0.05 suggesting a significant
correlation (A, B, C, D).
doi:10.1371/journal.pone.0033969.g002
Figure 3. The neutralizing targets were determined for 116 out of the 128 HIV-uninfected participants and 68 out of the 70 HIV-
infected participants after excluding participants with high titers of anti-Ad35 Nab which confound categorization. (A). Pre-existing
Nab titers in HIV-uninfected (n=75) and HIV-infected (n=57) participants were compared among participants with low anti-Ad35 titers (titer,12) (B).
Geometric mean and 95% CI was shown in the background of Nab titers in each individual.
doi:10.1371/journal.pone.0033969.g003
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immune responses to HIV antigens in the HIV-uninfected
subjects
We next compared the magnitude of IFN-c and/or IL-2
secreting CD4
+ or CD8
+ T cells specific to HIV antigens between
the seropositive and seronegative groups with data from the
HVTN immunology laboratory from the 179 participants who
were all in the vaccine group at week 30. The presence of pre-
existing Nab to either Ad5 (Table 1), the capsid (Table 2), or the
fiber (Table 3) all correlated with reduced vaccine-induced
immunogenicity, especially evident in the lower CD8 T-cell
frequencies recognizing Gag, Pol, and Nef. As shown in Table 1,
for example, in the Ad5 seronegative group, the median HIV Gag-
specific CD8 frequency was 0.088%. In contrast, in the Ad5
seropositive group, the response was significantly reduced to
0.017% (p,0.0001). This reduction in the immune response
correlated more closely with the Nab directed to Ad5 fiber
(Table 3) than capsid (Table 2) based on the p-value when CD8
immune responses in seronegatives and seropositives were
compared. In contrast, CD4 responses were less affected by Ad5
seropositivity, especially those directed to Gag and Pol. The anti-
Gag and anti-Pol-specific CD4 responses were similar in both Ad5
seropositive and seronegative groups (p.0.05, Table 1). CD4
responses directed to Nef were somewhat reduced in the Ad5
seropositive group (p,0.05, Table 1), suggesting that immune
effects were dependent to some extent on the antigen.
Characterization of Ad neutralizing antibodies in HIV-
infected subjects
In the trial, at the time of this analysis, a total of 71 participants
acquired HIV infection after vaccination in the placebo and
vaccine groups. To determine whether susceptibility to HIV
infection was related to the specificity of pre-existing anti-Ad5
Nabs, we evaluated the specificity of the response and their effects
on vaccine immunogenicity. Sera from 70 of these individuals
were pre-existing seropositive for Ad5, of which 26 sera were
derived from the placebo group and 44 from vaccinees. There was
no significant difference between the placebo and vaccine groups
in the titer of Nab to Ad5, Ad5 F35 (capsid), Ad35, or Ad35 F5
(fiber) (Figure S1, p.0.05). The majority of the sera contained
both anti-capsid and anti-fiber Nab (Figure 3A). These included 61
out of 68 subjects (Figure 3A, 90%), with two sera excluded due to
high anti-Ad35 Nab titer. These findings were not unexpected
because of the high rates of pre-existing Ad5 immunity within this
subgroup. Most of the remaining sera contained anti-fiber Nab
exclusively (9%). When the titer of anti-Ad5 (p=0.8), capsid
(p=0.5), or fiber (p=0.4) responses were compared between
circumcised (n=30) and non-circumcised (n=31) males, no
significant difference between these two groups was evident.
To reveal any unique features of anti-Ad5 Nab in HIV-infected
subjects, we compared the titer of pre-existing Ad5 Nab in
uninfected and infected Ad5 seropositive groups, including
placebo and vaccine groups, as well as Ad35 seronegative
participants. This comparison revealed no significant difference
in the titer of anti-Ad5 in these two groups (Figure 3B). At the
same time, a significantly lower anti-Ad5 capsid Nab titer
(Figure 3B, geometric mean 597 vs. 1149, p=0.03) was observed
in HIV-infected individuals. This trend was also reflected in the
distribution of Ad5 Nab neutralizing targets as shown in Figure 3A.
For example, while Nab to capsid only was detected in a small
portion of HIV-uninfected subjects (7%), it was seen even more
rarely in HIV-infected participants (Figure 3A, 1%). We also
analyzed the HIV uninfected and infected Ad5 seropositive groups
based on Ad35 seropositivity. In the HIV-infected group, 13
participants had pre-existing Nab to anti-Ad35 (Table 4, 19% of
the total). In contrast, 53 (41%) of the 128 HIV-uninfected
participants were Ad35 seropositive. The Ad35 seroprevalence
was therefore significantly lower in the HIV-infected group
compared to the HIV-uninfected group (p=0.002). On the other
hand, the seroprevalence for Ad14 (serotype B), Ad28 (serotype D)
and Ad41 (serotype F) in these two groups were not significantly
different (Table 5). These findings suggested that these HIV-
susceptible individuals had a unique immune profile to Ad5 capsid
and Ad35, both prior to vaccination and afterwards, that may
have predisposed them to HIV-1 infection.
Discussion
rAd vectors are widely used in the field of gene therapy and
vaccination due to their efficiency for gene delivery and ability to
stimulate cellular and humoral immune responses. However, the
potential effects of pre-existing immunity to Ad on vector delivery
and vaccine efficacy raise complications for clinical implementa-
tion. In the Phase IIB Step trial, the high rates of infection in the
vaccine group, along with the lack of protective efficacy, led to
termination of the study. These concerns highlight the need to
understand the role of anti-vector immunity and its impact on
Table 1. Pre-existing anti-Ad5 neutralizing antibodies reduced immune responses generated by MRKAd5 HIV-1 gag/pol/nef
vaccine, especially HIV-specific CD8+ immune responses.
IFN-c
+ and/or IL-2
+ Median Frequency (%)
Specific T cells Ad5 seronegative (n=36–39) Ad5 seropositive (n=66–75) p value
Gag CD4 0.064 (0.041–0.083) 0.060 (0.032–0.099) 0.4
CD8 0.088 (0.051–0.236) 0.017 (0.000–0.090) ,0.0001***
Nef CD4 0.040 (0.015–0.071) 0.018 (0.003–0.036) 0.007***
CD8 0.271 (0.121–0.819) 0.080 (0.009–0.307) 0.0005***
Pol CD4 0.017 (0.003–0.041) 0.012 (0.000–0.030) 0.3
CD8 0.112 (0.044–0.316) 0.042 (0.009–0.106) 0.001**
Median (25%–75% percentile),
*: p,0.05;
**: p,0.01,
***: p,0.001.
doi:10.1371/journal.pone.0033969.t001
Immune Basis of HIV-1 Infection in Step Trial
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the efficiency of gene delivery and may cause side effects on disease
outcomes. Despite substantial effort, no causal link has been
established between Ad5 seropositivity, the MRKAd5 vaccination,
and the risk of HIV acquisition, although retrospective analyses
suggest a higher risk of infection after vaccination in Ad5
seropositive, uncircumcised participants [1].
Several hypotheses have been proposed to explain this trend.
One is that the rAd5 vector may activate pre-existing Ad5-specific
CD4 T cells to express HIV co-receptors in Ad5 seropositives [6].
However, it was shown that there is no correlation between Ad5
serostatus and the presence of anti-Ad5 T-cell responses in
humans [7,8]. Furthermore, there was no elevated, long lasting
reactivation of Ad5-specific CD4+ T-cell responses after rAd5
vaccination in seropositive populations [7,8]. Therefore, it is
unlikely that Ad5-specific CD4+ T cells reactivated by vaccination
resulted in increased HIV targeting cells in the systemic
compartment. Recent studies in monkeys and in Step participants
have also suggested that there is no greater reactivation or
trafficking of CD4+ T cells to mucosal compartments in Ad5
seropositives compared to Ad5 seronegatives post-vaccination [9].
Another hypothesis is that anti-Ad5 neutralizing antibodies can
form immune complexes with rAd5 vectors and dendritic cells
which can enhance HIV infection in T cells. Although this
possibility was demonstrated in vitro [10], it is unknown how it
correlates to the responses found in the high risk group of the Step
trial.
In this study, we analyzed the specificity of anti-Ad5 Nab in
Step trial participants and determined whether differences in
specificity correlated with Ad5 seropositivity and risk for HIV
infection. The seroprevalence reported here for Ad5 is higher than
assayed by HVTN as 9 out of the 60 seronegatives were
seropositive by our assay. This is likely due to the use of EDTA
for harvesting cells rather than trypsin, which can cleave CAR and
compromise physiological functions that require intact CAR
protein [11]. Trypsin may also cleave other cellular receptors,
including integrins that affect virus uptake [12]. Although the
proteolysis of CAR by trypsin is limited to one cleavage site,
trypsin treatment may affect the sensitivity of the assay to detect
neutralizing antibodies to other rAd that use trypsin-sensitive
cellular receptors [13]. The results show that the MRKAd5 HIV
vaccine efficiently converted all the Ad5 seronegative participants
to seropositivity after a single vaccination. Thus, pre-vaccine
serostatus was not maintained, even at four weeks after the first
vaccination. Our data also suggest that vaccination induced Nab
to the capsid of Ad5 more efficiently than to the fiber. This result is
consistent with a previous study that showed differences in the
specificity of Ad5 Nab from natural infection and vaccination with
Table 2. Pre-existing anti-Ad5 capsid neutralizing antibodies reduced immune responses generated by MRKAd5 HIV-1 gag/pol/
nef vaccine, especially HIV-specific CD8+ immune responses.
IFN-c
+ and/or IL-2
+ Median Frequency (%)
Specific T cells Ad 5 capsid seronegative (n=41–44) Ad5 capsid seropositive (n=66–74) p value
Gag CD4 0.064 (0.037–0.078) 0.063 (0.033–0.106) 0.9
CD8 0.067 (0.027–0.209) 0.016 (0.000–0.103) 0.001**
Nef CD4 0.037 (0.011–0.071) 0.023 (0.004–0.038) 0.03*
CD8 0.215 (0.087–0.717) 0.088 (0.008–0.430) 0.01*
Pol CD4 0.014 (0.000–0.040) 0.014 (0.002–0.036) 0.9
CD8 0.101 (0.032–0.228) 0.046 (0.011–0.121) 0.03*
Median (25%–75% percentile),
*: p,0.05;
**: p,0.01,
***: p,0.001.
doi:10.1371/journal.pone.0033969.t002
Table 3. Pre-existing anti-Ad5 fiber neutralizing antibodies reduced immune responses generated by MRKAd5 HIV-1 gag/pol/nef
vaccine, especially HIV specific CD8+ immune responses.
IFN-c
+ or IL-2
+ Median Frequency (%)
Specific T cells Ad 5 fiber seronegative (n=43–47) Ad5 fiber seropositive (n=59–69) p value
Gag CD4 0.064 (0.044–0.081) 0.064 (0.031–0.108) 0.8
CD8 0.088 (0.027–0.237) 0.017 (0.000–0.075) 0.0002***
Nef CD4 0.034 (0.011–0.069) 0.024 (0.003–0.041) 0.09
CD8 0.271 (0.092–0.816) 0.081 (0.010–0.297) 0.002**
Pol CD4 0.014 (0.000–0.040) 0.014 (0.002–0.036) 0.8
CD8 0.103 (0.044–0.300) 0.034 (0.009–0.106) 0.0009***
Median (25%–75% percentile),
*: p,0.05;
**: p,0.01,
***: p,0.001.
doi:10.1371/journal.pone.0033969.t003
Immune Basis of HIV-1 Infection in Step Trial
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efficiently than to fiber, while natural infection generated Nab to
both Ad5 fiber and capsid. This may be due to the fact that the
rAd vaccines are non-replicating and contain more capsid proteins
than fiber proteins. In the Step trial, we show here that one
vaccination was sufficient to convert all vaccinees to Ad5 capsid
seropositivity, while three vaccinations converted them all to Ad5
fiber seropositivity. Therefore, pre-vaccination serostatus affected
post-vaccination neutralizing antibody profiles and the quantity of
anti-Ad5 fiber Nabs. There is no evidence to suggest that such
quantitative differences in the titers of anti-Ad5 fiber Nab between
these two groups correlated with HIV infection risk in the
participants.
There were no significant differences in the titer of Ad5
neutralizing antibodies between HIV-infected and uninfected
participants, and no significant differences among HIV-infected
participants in the vaccine and placebo groups (Figure S1). These
data are consistent with a recent report showing that anti-Ad5
neutralizing antibody is not associated with risk of HIV infection
in the absence of vaccination [14]. On the other hand, further
analysis of HIV-infected participants showed that their sera tend
to contain lower anti-Ad5 capsid Nabs compared to that detected
in uninfected participants. It seems that anti-vector immunity
differed qualitatively in participants who acquired HIV infection
compared to those who did not.
This finding highlights the fundamental differences in these
participants in terms of how their immune systems recognize
multiple components of viral antigens. Although our assay did not
distinguish anti-hexon and anti-penton antibodies targeting the
viral capsid, previous studies have demonstrated that anti-hexon
and anti-fiber antibodies play a major role in mediating
neutralization in Ad5 seropositive people and subjects vaccinated
with rAd5 vectors [5,15–17]. Anti-penton antibodies have also
been detected in cancer patients receiving rAd5 therapies [18].
Therefore, the anti-capsid antibodies documented here are likely
composed of both anti-hexon and anti-penton antibodies, with
anti-hexon antibodies as the major contributor to neutralization.
As shown here, multiple neutralizing epitopes targeted by the
immune system exist for adenoviruses. These epitopes can be
serotype-specific or located in conserved regions among adenovir-
idae. It has been documented that Ad fiber-specific neutralizing
antibodies are more serotype-specific and Ad capsid-targeted
antibodies are group-specific with a broader spectrum [19,20]. It
seems that HIV-infected participants had lower baseline Ad5
capsid neutralizing antibodies compared to HIV-uninfected
participants. It is interesting to note that 41% were Ad35
seropositive among the Ad5 seropositive HIV-uninfected partic-
ipants compared to 19% Ad35 seropositive among the Ad5
seropositive HIV-infected subjects. This difference does not reflect
the lack of exposure to other adenovirus serotypes in the 70 HIV-
infected subjects as the seroprevalence for other serotypes
including Ad14, Ad28 and Ad41 in the Ad5 seropositive HIV-
infected subjects is not significantly different from that in the HIV-
uninfected Ad5 seropositives. It is quite possible that the infection
rates were comparable but the HIV-infected cases did not
generate a strong, long-lasting humoral response to a weakly
immunogenic pathogen like Ad35. The data on magnitude of Ad5
titers and immune responses after vaccination and the correlations
with subsequent HIV infection suggest that differences in immune
function may predispose to infections seen in the Step study.
We also document differential effects of baseline Ad5 serostatus
on CD4 and CD8 immune responses stimulated by the MRKAd5
HIV vaccine. The blunting effects of pre-existing Ad5 immunity
were more apparent on the magnitude of CD8 responses than on
CD4 responses. In the case of specific responses to Gag and Pol,
Ad5 serostatus only affected CD8 responses to these two antigens.
On the other hand, Ad5 serostatus reduced both CD4 and CD8
responses to Nef. Such differential effects on immune responses to
different antigens were observed in DNA/rAd5 HIV vaccine
trials: Ad5 serostatus had no effect on immune responses to HIV
Env but affected anti-Gag immune responses [5]. Such blunting
can affect vaccine immunogenicity in Ad5 seropositives and the
boosting effect of vaccinations after the first in Ad5 seronegatives.
Thus, a heterologous prime and boost regimen may further
improve vaccine efficacy even in Ad5 seronegative subjects.
In summary, this study shows that the MRKAd5 HIV vaccine
generated neutralizing antibodies to Ad5 hexon and penton capsid
proteins more efficiently than to Ad5 fiber. Anti-vector immunity
differed qualitatively in participants who acquired HIV infection
compared to those who did not. This effect was independent of
vaccination and may have arisen in part because of differences in
the immune function of subjects enrolled from distinct geographic
regions or HSV seropositivity or infection by other viruses. The
increased HIV infection rates in Step were therefore confounded
by these underlying increased risk factors and not clearly related to
the vaccine. Pre-vaccination serostatus affected post-vaccination
neutralizing antibody profiles and vaccine-induced immune
responses to HIV antigens. These data also suggest that Nab to
Ad5 fiber contributes to the reduction of vaccine potency. Thus,
strategies to overcome pre-existing Nab must avoid the use of Ad5
fiber for vector construction.
Materials and Methods
Construction and Production of Adenovirus Vectors
The construction and propagation of the rAd5 and rAd35
vectors with wild-type capsid proteins and with chimeric fiber were
previously described [21–23]. Total particle unit titer was
determined by absorbance [24]. The transduction activity of these
Table 4. Seroprevalence of Ad35 in HIV-infected, Ad5
seropositive participants is lower compared to that in HIV-
uninfected, Ad5 seropositive participants.
HIV-infected HIV-uninfected
Ad35 seropositive 13* 53*
Ad35 seronegative 57* 75*
Total (% Ad35 seropositive) 70 (19%) 128 (41%)
*values used for Fisher’s exact test, p=0.002.
doi:10.1371/journal.pone.0033969.t004
Table 5. Seroprevalence of Ad14, Ad28 and Ad41 in HIV-
infected, Ad5 seropositive and HIV-uninfected, Ad5
seropositive participants is similar.
HIV-infected
HIV-
uninfected P*
Ad14 seroprevalence 51% 56% 0.5
Ad28 seroprevalence 58% 69% 0.2
Ad41 seroprevalence 94% 99% 0.1
*Fisher’s exact test.
doi:10.1371/journal.pone.0033969.t005
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sensitive range of MOI that can be used in neutralizing assays [5].
Clinical Trials and Serum Samples
The Step trial is a Phase IIB, placebo-controlled trial with 3000
participants who received three intramuscular injections of either
rAd5 HIV vaccine expressing HIV-1 gag/pol/nef or the vaccine
diluent at day 0, week 4, and week 26 as previously described [1].
The trial was stopped due to lack of vaccine efficacy and futility. A
trend towards increased HIV infection frequency was observed in
vaccinated subpopulations, though it did not reach statistical
significance.
To follow the development of anti-Ad5 neutralizing antibodies
during vaccination, eighty-eight Step trial serum samples were
received from the HVTN. These samples were from 11 randomly
selected Ad5 seronegative and 11 randomly selected Ad5
seropositive participants collected on vaccination Day 0 and
following each of the three MRKAd5 vector administrations (week
4, week 8, and week 30). The majority of the 22 participants were
from North America (US or Canada, 68%) and the rest were from
the Caribbean (Haiti or Puerto Rico, 18%) or South America
(Peru, 14%).
To analyze the effect of pre-existing anti-Ad5 neutralizing
antibodies on vaccine immunogenicity, human serum samples
from 179 Step participants in the vaccine group were analyzed
and immunogenicity data from these participants as measured by
ICS assay at Week 30 were obtained from HVTN. Among the 179
participants, 51 were Ad5 seronegatives selected randomly. The
rest were Ad5 seropositive participants at Day 0 and the titers of
anti-Ad5 neutralizing antibodies in these participants were
distributed evenly among low, mid and high ranges as previously
determined by HVTN [2]. The majority of the participants were
from North America (USA or Canada, 60%), the rest of them
were from South America (Peru or Brazil, 22%), the Caribbean
(Haiti or Dominican Republic, 17%) or Australia (1%).
71 Step trial serum samples collected on vaccination Day 0 from
Ad5 seropositive participants who acquired HIV post-vaccination
were also analyzed to reveal particular features of their anti-Ad5
neutralizing antibody profiles. These were all the HIV positives in
the Step trial at the time of analysis. 64 of the participants were
male with 30 circumcised, 32 uncircumcised, 2 unknown. The
majority of them were from North America (USA or Canada,
59%), the rest were from South America (Peru or Brazil, 36%) or
the Caribbean (Haiti or Dominican Republic, 5%).
Neutralization of Adenovectors with Human Sera
The method for analyzing the neutralization of adenovectors by
human sera was developed based on procedures published
previously [5]. The sera were inactivated by heating at 56uC for
60 min and the inactivated sera were diluted with 10% FBS
containing RPMI medium and mixed with the indicated rAd
vector encoding luciferase for 30 min at room temperature for
neutralization. To prepare A549 cell suspensions for transduction,
cells grown in a 75 cm
2 flask were harvested by treatment with
4 mM EDTA and suspended in 10% FBS containing RPMI
medium. The neutralized virus was used to transfect A549 cells at
100 PU/cell, and luciferase expression was analyzed using the
luciferase assay kit (Promega, Inc.) at 24 h post-transduction. The
serum at the dilution of 1:18 that reduced viral transduction
activity by more than 90% was defined as seropositive [1]. The
neutralization titer for such seropositive sera was also determined
and defined as the maximum dilution that can reduce the viral
transduction by 90% [25] as calculated using GraphPad Prism 5
software. A typical neutralization graph is shown in Figure S2.
Analysis of T-cell Responses Post-vaccination
At 30 weeks after the first vaccination (four weeks post-third rAd
vaccination), the T-cell responses to individual HIV-1 vaccine-
matched peptide pools were analyzed according to previously
published methods by an intracellular cytokine staining (ICS) assay
[2]. The percentages of CD4+ and CD8+ T cells producing
cytokines were reported with background correction. ICS data for
some of the participants were not available at the time of analysis
and the numbers of available data were noted in each figure and
table.
Statistical Analysis
The Nab titer and the magnitude of CD4+ or CD8+ T-cell
immune responses were compared between seropositive and
seronegative subjects using two-sided Wilcoxon Rank-Sum tests.
These non-parametric tests were chosen due to the presence of
large influential points, and the moderate sample sizes.
Supporting Information
Figure S1 The titers of Nab to Ad5, Ad5 F35, Ad35, and
Ad35 F5 were determined in HIV-infected participants
in the placebo (n=26) and vaccine group (n=44).
Geometric mean and 95% CI are shown in the background of
Nab titers in each individual.
(PDF)
Figure S2 Neutralizing activity of a representative
human serum (participant ID 13958) against rAd is
shown. This serum contained high titers of neutralizing
antibodies to Ad5, Ad5 F35 and Ad35 F5, with minimal Ad35
neutralizing antibodies.
(PDF)
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